Tag archive for ‘biopharmaceutical’
Jewish Business News On Thursday, February 26th, 2015

RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage

RegeneRx Biopharmaceuticals, Inc, an American publicly traded, clinical-stage, biopharmaceutical company, has received an Israeli patent with claims for preventing, inhibiting or reducing heart tissue More...

Jewish Business News On Tuesday, February 17th, 2015

Biotech Investor Alex Rabinovich Increases Stake in Israel’s XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., an Israeli clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical More...

Gil Tanenbaum On Saturday, January 3rd, 2015

Israeli-American Biomed Firm Chiasma Raises $33.8 Million to Continue Development of Oral Meds

Israeli biomed company Chiasma has raised $33.8 million out of a planned total $56.3 million round of fundraising. It plans to use the infusion of new capital to continue the development of its oral octreotide. MPM More...

Gil Tanenbaum On Wednesday, October 15th, 2014

Therapix to Trade ADRs

Therapix Biosciences, a biopharmaceutical Israeli-based company that recently expanded into the field of medical marijuana, has registered with the American Depository Receipts to begin trading of its ADRs. As More...

Gil Tanenbaum On Wednesday, September 10th, 2014

Israeli BiondVax Gets $1.34 Million to Develop Universal Flu Vaccine

Israeli firm BiondVax, a biopharmaceutical company developing a Universal Flu Vaccine, has been awarded $1.34 million from Israel’s Chief Scientist in the Ministry of Economy to promote the company’s More...

CEO biolinerx
Jewish Business News Service On Monday, December 16th, 2013

Israeli BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment

– Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) –  CEO Kinneret Savitsky – BioLineRx (NASDAQ: BLRX; TASE: BLRX), More...

OphthaliX : European Patent Office Grants a Patent for the Treatment of Sjogren’s Syndrome

– – Israeli OphthaliX Inc. (OTC BB: OPLID),  announced that the European Patent Office issued a Certificate of Grant of Patent for European Patent No. 1778239 entitled “Adenosine A3 receptor More...

Israeli generic giant Teva and Swiss Lonza end their joint venture

– – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Switzerland’s Lonza Group AG (SXW: LONN) announced today that, following a strategic review of the Teva-Lonza joint venture, More...

Wordpress site Developed by Fixing WordPress Problems